Pasithea Therapeutics Corp. (KTTA) Stock Price & Analysis
Pasithea Therapeutics Corp. (KTTA) fell 0.07% to USD 0.58 as of September 8, 2026 at 06:57 UTC, according to Nexqual real-time market data.
KTTA last closed at USD 0.58; the session ranged USD 0.57–0.59 on volume of 222,701 shares. Market capitalization is —, with a 52-week range of USD 0.28–2.06 (NCM). Source: Nexqual, September 8, 2026 at 06:57 UTC.
Key Statistics (as of September 8, 2026 at 06:57 UTC)
| Price | USD 0.58 |
|---|---|
| Change | ▼ 0.07% (down) |
| Previous Close | USD 0.58 |
| Open | USD 0.58 |
| Day Range | USD 0.57 – 0.59 |
| 52-Week Range | USD 0.28 – 2.06 |
| Volume | 222,701 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (KTTA)
Nexqual's technical model rates KTTA "BUY" based on 5 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 06:57 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.52 (neutral) |
| vs SMA50 | Above (USD 0.5) |
| MACD | 0.02 (positive) |
From Pasithea Therapeutics Corp.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Our policy is to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our current product candidates and any future product candidates, proprietary information and proprietary technology through a combination contractual arrangements and patents, both in the United States and abroad.
- While we believe that our technology, development experience and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic institutions, governmental agencies and public and private research institutions.
Partnerships
- To date, we have created over 100 analogs of our 20 priority hits as provided via our past screening partnership with Evotec.
- The terms of the Alpha-5 Agreement were approved by (i) the disinterested members of the audit committee ("Audit Committee") of Board and (ii) the disinterested members the Board, under the Company's related party transaction policy.   In connection with the Alpha-5 Agreement, each of the employees of Alpha-5 entered into employment agreements with the Company.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ISPC | iSpecimen Inc. | USD 1.54 | ▲ 3.36% |
| BFRI | Biofrontera Inc. | USD 1.61 | ▲ 5.92% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.46 | ▲ 2.93% |
| PTPI | Petros Pharmaceuticals, Inc. | USD 0.01 | ▲ 20% |
| SOPAQ | Society Pass Incorporated | USD 0 | ▼ 33.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:57 UTC. This page is informational and not investment advice.